Free Shipping on Orders $150+

For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.

NAD+

4.8 (238)

Longevity Research Compound

Dosage

Quantity

1

Price

$62.99

Free shipping on orders $150+

60-day money-back guarantee

Secure checkout

Made in the USA

Certificate of Analysis

Batch verified lab data

Latest

99.93%

Purity

Variant
NAD+ 500mg
Lot #
A0112
Labeled
20mg
Actual
22.56mg
Tested
Feb 4, 2026

Frequently Researched Together

View all

Semaglutide

Metabolic Research Peptide

$34.99

View

GHK-Cu

Anti-Aging Compound

$26.99

View

MOTS-c

Metabolic & Longevity Peptide

$34.99

View

BPC-157

Regenerative Peptide

$29.99

View

Research Purposes Snapshot

Educational reference from human cohort and mechanistic literature. Not FDA approved for therapeutic use.

1,518

Human cohort

Large-scale participant count in published aging-focused NAD+ blood studies.

ATP

Energy metabolism

Central to mitochondrial redox balance and ATP-generating pathways.

500+

Cellular processes

Essential cofactor role across hundreds of enzymatic reactions.

7

Sirtuin activation

Seven mammalian sirtuins (SIRT1–7) draw on NAD+ as a substrate.

50%

Decline by ~age 50

Substantial NAD+ drop relative to youthful baselines is commonly reported by midlife in tissue summaries.

Physical properties

Handling & storage

Stability expectations for research-grade material.

Appearance
White to off-white powder
Solubility
Freely soluble in water
Powder storage
−20°C, protect from light
Prepared solution
Use promptly; refrigerate

Documented research roles

High-level functions described in scientific literature.

SIRT1–7

Sirtuin axis

Essential substrate for sirtuin-mediated signaling.

DNA context

Genomic integrity

Tied to damage-response and repair enzyme networks.

ATP / redox

Energy metabolism

Central to mitochondrial electron transport and ATP generation.

Coenzyme

500+ pathways

Cofactor in hundreds of documented enzymatic reactions.

Redox & ATP

Mitochondrial support

NAD+ participates in electron transport and oxidative phosphorylation pathways.

Electron transport (model systems)95%
ATP synthesis context90%
Redox balance markers85%

DNA maintenance

PARP & consumption

NAD+ fuels PARP-family enzymes that respond to strand breaks and base damage.

  • PARP1 — single-strand break repair context
  • PARP2 — base excision repair involvement
  • CD38 — immune-related NAD+ turnover

Note: PARP and CD38 activity can increase with age, increasing NAD+ demand in some models.

Longevity signaling

Sirtuin-mediated effects

Sirtuins link NAD+ availability to metabolic and stress-response programs.

  • SIRT1 — metabolism & inflammation
  • SIRT3 — mitochondrial function
  • SIRT6 — DNA repair & stability
  • SIRT7 — stress response
Yang et al. 2022

1,518

Participants in aging-focused NAD+ cohort

Blood NAD+ decline (reported)

Men−34.5 µmol/L
Women−31.3 µmol/L
Summary: NAD+ declined with age, with a steeper association in men; slopes were more pronounced after roughly age 60 in reported models (β ≈ −1.12 in 40–49 band; β ≈ −2.16 after 60 in stratified analyses).

Consult primary publication for methods & statistics

Cohort profile

Population descriptors

Large community-based adult sample with LC-MS/MS NAD+ quantification.

Participants with NAD+ measured100%
Male (gender-stratified analysis)52.6%
Mean age (years)43.0

Adults 18+ in reported cohort

Assay validation noted in primary report.

Safety reporting context

Often discussed in IV infusion literature: generally mild, rate-sensitive adverse events.

Commonly cited mild effects

40%

Nausea

Mild
35%

Flushing / warmth

Mild
25%

Chest tightness

Mild
20%

Headache

Mild
15%

Dizziness

Mild
10%

Abdominal cramping

Mild

Infusion dynamics

Rate-dependent effects

Symptoms are frequently attributed to infusion speed rather than cumulative dose alone.

  • Slower rates often reduce subjective intensity
  • First exposure may feel strongest
  • Tolerance commonly improves with repeated sessions

Mitigation strategies

Infusion pacing
Lowers most AEs
Hydration
May reduce headache risk
Pause if needed
Resume after rest

Many effects resolve when the infusion is slowed or paused; intensity often drops on subsequent visits.

Precautions cited in clinical discussion

  • Cardiac rhythm issues — rare, often in predisposed individuals
  • Severe hypotension — very rare
  • Hypersensitivity — extremely rare
  • Pregnancy / lactation — not established in trials

Researcher notes

  • Clinical-grade administration belongs under qualified supervision.
  • Conservative starting exposure is commonly recommended for first-time recipients.
  • Disclose medications and comorbidities to the treating team.
  • Maintain hydration before, during, and after infusion protocols when applicable.

Important Research Notice

Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.